Endo International PLC
What Does Valeant’s Institutional Ownership Look Like?
Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.
Why did Lone Pine open a position in IntercontinentalExchange?
Lone Pine Capital opened a new 2.19% position in IntercontinentalExchange Group, Inc.
Yes, There Will Be Margin Erosion for Valeant in 2017
Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.
Analyst Ratings for Endo International and Peers in August
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.
Why did Lone Pine Capital buy a stake in SBA Communications?
SBA Communications Corporation is a 2.11% position initiated by Lone Pine Capital in 4Q 2013.
How Did Valeant Fare in 2Q16?
Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.
What Do Analysts Recommend for Valeant after Recent Happenings
The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.
Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016
Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.
Point72 Reduces Its Stake in Valeant Pharmaceuticals
Point72 reduced its stake in Valeant Pharmaceuticals by selling 924,400 shares. It held 132,300 Valeant shares. Valeant accounted for 0.13% of the fund’s 4Q14 portfolio.
Glenview Capital raises position in Endo International
Glenview Capital Management added to its position in Endo International Plc (ENDP) in the third quarter. Currently, the position accounts for 2.02% of the fund’s total portfolio.
Shire Gets Dropped from AQR Capital’s Portfolio
During the fourth quarter of 2014, AQR Capital closed its position in Shire plc (SHPG). The fund sold its entire stake of 816,116 shares in the company.
What Are Analysts Recommending for TEVA and ENDP in May?
On May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close.
Analysts’ Views on Endo International and Mallinckrodt
Most analysts covering Endo International (ENDP) and Mallinckrodt (MNK) recommend “hold.” On March 5, Endo closed at $8.72, and Mallinckrodt closed at $22.39.
What Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
How Did Mallinckrodt’s Specialty Brands Perform in 2016?
Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.
Mallinckrodt’s Revenue Growth in Fiscal 4Q16
On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.
Teva Leads the Industry in First-to-File Applications in 2016
Teva Pharmaceutical (TEVA) is the leading generic pharmaceutical company in terms of first-to-file (or FTF) applications in the United States.
What Is Donald Trump’s Seven-Point Health Plan?
Trump’s healthcare agenda During his campaign, Trump came up with a seven-point plan for the healthcare industry. In this plan, he proposed to repeal the Affordable Care Act. Although a complete repeal doesn’t seem feasible, if applied, it would definitely take a toll on hospitals and insurance companies. In the next article, we’ll discuss the severity of […]
Valeant’s Salix Acquisition Saga
Valeant won the acquisition race for Salix by valuing it at $14.5 billion, inclusive of net debt. In April 2015, Valeant paid $158 per Salix share.
Valeant Looks to Boost Profit Margins through the Walgreens Deal
On December 15, 2015, Valeant Pharmaceuticals (VRX) announced its decision to enter into a fulfillment agreement with Walgreens.
Teva’s Research Pipeline and Generic Product Launches in 2016
The combined Teva Pharmaceutical–Allergan Generics company filed 65 ANDAs (Abbreviated New Drug Applications) in 2015.
The Truth behind Horizon’s EV-to-EBITDA Performance
On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.
High-Yield Bond Funds See Miniscule Inflows in Week Ended July 8
Net inflows into high-yield bond funds totaled $45.1 million in the week ended July 8. It was the smallest inflow so far this year. High-yield bond funds have seen inflows of $280 million year-to-date.
Endo International, a New Position for OZ Management
In 4Q14, Oz Management added a new stake in Endo International plc (ENDP) by purchasing 5,221,710 shares, representing 1.01% of the fund’s 4Q14 portfolio.
Priceline Group loses its position in Chilton Investment Company
Chilton Investment Company exited its position in Priceline Group Inc. (PCLN), which accounted for 1.19% of the fund’s 3Q14 portfolio.
Soros continues to be bullish on Dow Chemical
Soros Fund Management upped its position in Dow Chemical (DOW) in the fourth quarter. The position now accounts for 2.58% of the fund’s 4Q14 portfolio.
LyondellBasell is a brand new position in Soros’ 4Q portfolio
Netherlands-based LyondellBasell, which came out of chapter 11 bankruptcy in 2010, is one of the world’s top five independent chemical companies based on revenues.
Millennium Management increases its stake in NextEra Energy
Millennium Management increased its stake in renewable energy generator NextEra Energy Inc. (NEE) from 1,789,954 shares to 3,333,627 shares.
Israel Englander’s Millennium Management ups its stake in Perrigo
Millennium Management ups position in Perrigo Company PLC (PRGO) that currently accounts for 1.28% of the fund’s 4Q portfolio.
Millennium Management buys a new position in SunTrust Banks
Millennium Management started a new position in SunTrust Banks (STI) that accounts for 0.15% of the fund’s portfolio.
Why did Lone Pine Capital decide to move out of Equinix?
Lone Pine Capital exited a 1.78% position in Equinix, Inc. in 4Q 2013.